KetamineOne Announces Two Studies Focused On PTSD, Depression

KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not one, but two research studies. The studies will be centered around that of PTSD and depression.

The first study, classified as a single arm, open label study of persons with PTSD, will examine persons undergoing what is classified as proprietary physical therapy at the firms IRP Health Clinics. The study, which is to occur over 12 weeks, will study the ability of the program to alleviate pain and PTSD symptoms via exercise therapy, physiotherapy and pain neurophysiology education. The study is said to be observational in nature and will be lead by KGK Science.

The second study will be focused on patients whom suffer from depression that are receiving IV ketamine infusion therapy, with the study looking to collect biometric data and valid psychiatric instrument measures of efficacy of the therapy. The protocol for the study is currently being finalized, with the trial slated to begin late next monh.

Effectively, the latter study will look to provide further data on relapses of depression following ketamine infusion, and to provide further data on the timing of a booster therapy before relapses occur. The study will be conducted at the firms medical clinics.

“The launch of these inaugural studies by Ketamine One is a great milestone for our Company and a clear demonstration of the synergies being created between the subsidiaries of KGK Science and IRP Health. These studies represent full collaboration between all our divisions – KGK, IRP Health and our ketamine clinic network,” commented Adam Deffett, interim CEO of Ketamine One.

KetamineOne Capital last traded at $0.57 on the Neo.


FULL DISCLOSURE: KetamineOne is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover KetamineOne on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

$30,000 GOLD: How Trump’s Policies Could Trigger The Next Price Explosion | Simon Marcotte

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

KetamineOne Brings Scent-Enabled Virtual Reality To Psychedelic Therapy

KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments....

Wednesday, August 4, 2021, 08:12:47 AM

Cognetivity’s Assessment Tool To Be Deployed At KetamineOne Clinics Across North America

Cognetivity Neurosciences (CSE: CGN) will soon see its cognitive assessment tool for the early detection...

Wednesday, September 1, 2021, 08:22:59 AM

KetamineOne Sees Subsidiary Assist In Ketamine Clinical Trials

Ketamine continues to be a hot topic in terms of clinical trials, with KGK Science,...

Wednesday, October 6, 2021, 09:16:49 AM

KetamineOne Reports Fiscal Q1 2022 Financials: $2.0 Million In Revenue

KetamineOne Capital (NEO: MEDI) released this morning its financial reports for the fiscal quarter ended October...

Thursday, December 16, 2021, 11:49:00 AM

Ketamine One: Corporate Overview

KetamineOne Capital Ltd. (NEO: MEDI) is a Vancouver-based wellness company with a focus on becoming...

Wednesday, August 18, 2021, 02:33:00 PM